RepliCel Life Sciences Inc.

As of September 30, 2023, RepliCel Life Sciences Inc. has 65.00M shares outstanding.

These figures are as of September 30, 2023. The price-to-sales ratio is 19.78, and the price-to-book ratio stands at -0.57.

These figures are as of September 30, 2023. The EV/Sales ratio of 19.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of September 30, 2023, RepliCel Life Sciences Inc. maintains a current ratio of 0.13, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -0.62, indicating conservative leverage, while an interest coverage ratio of -758.49 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2023. Return on assets (ROA) is negative at -17.58, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 6.34, useful for judging operating efficiency across full business cycles.

Over the twelve months ended September 30, 2023, RepliCel Life Sciences Inc. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -387.01 and net profit margin of -19.59 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2023. Free cash flow yield is negative at -28.47: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -27.57, meaning RepliCel Life Sciences Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

RepliCel Life Sciences Inc.'s most recent stock split took place on August 10, 2016 with a 10:1 split ratio.

As of September 30, 2023, RepliCel Life Sciences Inc. has an Altman Z-Score of -208.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.